Appl. No. 10/552,315

Amdt. dated January 31, 2008

Reply to Office action of August 2, 2007

In the Specification:

Page 6, lines 17-21, please amend the paragraph as follows:

The orientation and motion activity of the animals has been studied for three minutes in a special activity meter (Varimex®). The intensity of ptosis and diarrhea has been assessed on the standard 4-point scale (Mashkovsky M. D., Andreeva N.I., Polezhaeva A.I. Pharmacology of Antidepressants. Moscow, Medicine Publishers, 1983, p. 194-199).

Page 16, in the Abstract, please amend the Abstract as follows:

The invention relates to medicine, more specifically towilderness medicine, disaster medicine, neurodynia andpsychiatrics. It is applied a new antidepressant - The Ncarbamoyl-methyl-4-phenyl-2-pyrrolidone (trade-names:Phenotropil, Karfedon), earlier known-as a drug-with hypotensive,
anti- ischemic, nootropic, anticonvulsant activity. The
invention prevents sedative and cholinergic effects, avoids the
development of a tolerance and withdrawal syndrome. The
invention widens the armoury of the stated purpose.

The invention relates to medicine, more specifically to antidepressant pharmacology which selectively improves a diminished mood dominated by asthenic emotions. The inventive antidepressant substance is embodied in the form of N-carbamoyl-

Appl. No. 10/552,315

Amdt. dated January 31, 2008

Reply to Office action of August 2, 2007

methyl-4-phenyl-2-pyrrolidone. The invention increases the evidence of antidepressant effect after a single dose, prevents sedative and cholinergic effects, avoids the development of a tolerance and withdrawal syndrome during a course of application and allows for the unrestricted use of said substance for professional activity.